Development

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Development of Gamma-Delta T-Cell Therapies

Activation and expansion are essential for success in both autologous and allogeneic therapies.

QbD for Small-Molecule Continuous Process Development

Continuous manufacturing and a quality-by-design development approach are a natural fit.

Participants for START Pilot Program Selected by FDA

June 29, 2024

The seven chosen sponsors will help accelerate development of novel drugs and biologics for rare diseases.

AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

June 29, 2024

This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.

Roche Attains European Recommendation for Retinal Vein Occlusion Treatment

June 28, 2024

Vabysmo, already approved for patients with RVO in the US and Japan, would be the first bispecific antibody treatment for the condition in Europe.

Data from Study of Teva’s Ajovy Suggests Change to Migraine Treatment Pause Protocols

June 28, 2024

The typical cycle of ceasing and then reinitiating fremanezumab treatments may actually result in increased monthly migraine days, the study said.

Johnson & Johnson Completes Proteologix Acquisition, Gains Bispecific Antibody Assets

June 28, 2024

Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition.

Lantheus Acquires Rights to Life Molecular’s RM2 Targeting GRPR for Prostate and Breast Cancers

June 27, 2024

GRPR, or gastrin-releasing peptide receptor, is part of the bombesin G protein-coupled receptor family and has been found to be overexpressed in multiple cancers.

AstraZeneca Lung Cancer Treatment Approved in China

June 27, 2024

Results of a Phase III trial showed that Tagrisso with the addition of chemotherapy reduced the risk of disease progression or death associated with EGFR-mutated non-small cell lung cancer by 44%.

AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients

June 20, 2024

Imfinzi (durvalumab) combined with chemotherapy decreased the risk of disease progression or death by 58% in a 700-patient trial.

Roche and Ascidian Therapeutics Collaborate on Treatments for Neurological Diseases

June 18, 2024

The research collaboration and licensing agreement will focus on the discovery and development of RNA exon editing therapeutics.

Lamassu Pharma Bridges Scientific Knowledge and Patient Care

June 17, 2024

Gabi Hanna, MD, CEO and co-founder of Lamassu Pharma talks about a novel oncology platform and the link between science and patient care.